SI1771446T1 - Azaindolni zaviralci mtp-ja in apob-ja - Google Patents

Azaindolni zaviralci mtp-ja in apob-ja

Info

Publication number
SI1771446T1
SI1771446T1 SI200530353T SI200530353T SI1771446T1 SI 1771446 T1 SI1771446 T1 SI 1771446T1 SI 200530353 T SI200530353 T SI 200530353T SI 200530353 T SI200530353 T SI 200530353T SI 1771446 T1 SI1771446 T1 SI 1771446T1
Authority
SI
Slovenia
Prior art keywords
apob
mtp
azaindole
inhibitors
azaindole inhibitors
Prior art date
Application number
SI200530353T
Other languages
English (en)
Inventor
Alyx Caroline Guevel
Catherine Vidal
Bruno Roux
Olivier Chevreuil
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI1771446T1 publication Critical patent/SI1771446T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SI200530353T 2004-07-27 2005-06-28 Azaindolni zaviralci mtp-ja in apob-ja SI1771446T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408302A FR2873694B1 (fr) 2004-07-27 2004-07-27 Nouveaux aza-indoles inhibiteurs de la mtp et apob
EP05754288A EP1771446B1 (en) 2004-07-27 2005-06-28 Azaindole inhibitors of mtp and apob

Publications (1)

Publication Number Publication Date
SI1771446T1 true SI1771446T1 (sl) 2008-10-31

Family

ID=34948943

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530353T SI1771446T1 (sl) 2004-07-27 2005-06-28 Azaindolni zaviralci mtp-ja in apob-ja

Country Status (16)

Country Link
US (1) US7838533B2 (sl)
EP (1) EP1771446B1 (sl)
JP (1) JP5161569B2 (sl)
AR (1) AR050436A1 (sl)
AT (1) ATE398126T1 (sl)
AU (1) AU2005266662B2 (sl)
CA (1) CA2575223C (sl)
CY (1) CY1108306T1 (sl)
DE (1) DE602005007494D1 (sl)
DK (1) DK1771446T3 (sl)
ES (1) ES2308510T3 (sl)
FR (1) FR2873694B1 (sl)
PL (1) PL1771446T3 (sl)
PT (1) PT1771446E (sl)
SI (1) SI1771446T1 (sl)
WO (1) WO2006010423A2 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431602A1 (en) 2006-04-03 2019-01-23 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
JP5814505B2 (ja) 2006-04-03 2015-11-17 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008228243B2 (en) 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
JP2014518223A (ja) * 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
CN112263682A (zh) 2013-06-27 2021-01-26 罗氏创新中心哥本哈根有限公司 靶向pcsk9的反义寡聚体和缀合物
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
AU2002307839B2 (en) 2001-06-28 2006-03-16 Zoetis P Llc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
AU2003241907A1 (en) * 2002-05-31 2003-12-19 Yamanouchi Pharmaceutical Co., Ltd. Tetrahydropyran derivative
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
JP4737495B2 (ja) * 2004-01-14 2011-08-03 塩野義製薬株式会社 エリスロマイシン誘導体

Also Published As

Publication number Publication date
EP1771446B1 (en) 2008-06-11
WO2006010423A2 (en) 2006-02-02
US20090036481A1 (en) 2009-02-05
ATE398126T1 (de) 2008-07-15
WO2006010423A3 (en) 2006-03-02
FR2873694A1 (fr) 2006-02-03
CA2575223A1 (en) 2006-02-02
EP1771446A2 (en) 2007-04-11
AR050436A1 (es) 2006-10-25
US7838533B2 (en) 2010-11-23
CA2575223C (en) 2013-08-06
JP5161569B2 (ja) 2013-03-13
FR2873694B1 (fr) 2006-12-08
AU2005266662A1 (en) 2006-02-02
JP2008508198A (ja) 2008-03-21
AU2005266662B2 (en) 2011-04-21
DE602005007494D1 (de) 2008-07-24
CY1108306T1 (el) 2014-02-12
ES2308510T3 (es) 2008-12-01
DK1771446T3 (da) 2008-09-22
PL1771446T3 (pl) 2008-10-31
PT1771446E (pt) 2008-09-17

Similar Documents

Publication Publication Date Title
PL1771446T3 (pl) Azaindolowe inhibitory MTP oraz ApoB
EP1756092A4 (en) NEW INHIBITORS OF RHO-KINASEN
ZA200610593B (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of ß-secretase
IL176958A0 (en) Compounds and methods of use
ZA200701660B (en) Isoindoline compounds and methods of their use
TWI346663B (en) P38 inhibitors and methods of use thereof
IL181524A0 (en) Heterocyclic compounds and methods of use
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
PL378432A1 (pl) Inhibitory p38 i sposoby ich zastosowania
PL1940839T3 (pl) Pirydopirymidynonowe inhibitory PI3Kalfa
IL179398A0 (en) Dpp-ib inhibitors
ZA200704888B (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
EP1789437A4 (en) INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF
ZA200607582B (en) Anti-parasitic compounds and methods of their use
EP1817277A4 (en) PHENYL DERIVATIVES AND METHOD OF USE
EP1853632A4 (en) MODIFICATION OF AMINES AND ALCOHOLS
IL176772A0 (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
GB0400290D0 (en) dUTPase inhibitors
EP1883404A4 (en) P38 INHIBITORS AND METHODS OF USE
GB0422439D0 (en) Inhibitors of infection
GB0411145D0 (en) Protease inhibitors and their therapeutic applications
GB0504209D0 (en) New use of PDE7 inhibitors
GB0421356D0 (en) Inhibitors
GB0418435D0 (en) HDAC inhibitors and methods of use thereof